Tonix Pharmaceuticals has been given a breakthrough designation by the FDA for a PTSD therapy. The new drug is reported to use a formulation of cyclobenzaprine, which is already FDA-approved as a muscle relaxant.
This is good news for the many suffers of the syndrome and it follows a successful 2 year Phase II clinical trial, which concluded last year. The company has subsequently started recruiting military personnel into a Phase III of its clinical trial program.
It is believed the drug could alleviate common PTSD symptoms including disturbed sleep and nightmares. This breakthrough is likely to be well received by the many service personnel who suffer with the syndrome.
Read more HERE.